FIL Ltd Sells 454,036 Shares of CytomX Therapeutics Inc (NASDAQ:CTMX)

FIL Ltd reduced its holdings in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 80.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 112,956 shares of the biotechnology company’s stock after selling 454,036 shares during the quarter. FIL Ltd’s holdings in CytomX Therapeutics were worth $1,214,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Citigroup Inc. lifted its stake in shares of CytomX Therapeutics by 292.0% during the 4th quarter. Citigroup Inc. now owns 130,508 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 97,215 shares in the last quarter. Pictet Asset Management Ltd. lifted its stake in shares of CytomX Therapeutics by 0.9% during the 1st quarter. Pictet Asset Management Ltd. now owns 611,356 shares of the biotechnology company’s stock valued at $6,572,000 after buying an additional 5,670 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of CytomX Therapeutics by 3.3% during the 4th quarter. Victory Capital Management Inc. now owns 920,210 shares of the biotechnology company’s stock valued at $13,895,000 after buying an additional 29,810 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of CytomX Therapeutics by 12.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 174,545 shares of the biotechnology company’s stock valued at $3,229,000 after buying an additional 19,304 shares in the last quarter. Finally, Aquilo Capital Management LLC lifted its stake in shares of CytomX Therapeutics by 3.8% during the 3rd quarter. Aquilo Capital Management LLC now owns 674,763 shares of the biotechnology company’s stock valued at $12,483,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 81.83% of the company’s stock.

NASDAQ CTMX opened at $10.40 on Friday. CytomX Therapeutics Inc has a 1 year low of $8.94 and a 1 year high of $27.20. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21. The company has a market capitalization of $463.54 million, a price-to-earnings ratio of -5.12 and a beta of 0.51.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.22. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. The business had revenue of $29.49 million for the quarter, compared to analysts’ expectations of $13.59 million. As a group, research analysts forecast that CytomX Therapeutics Inc will post -2.13 EPS for the current fiscal year.

A number of brokerages recently commented on CTMX. ValuEngine upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. BidaskClub upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Nomura lowered their target price on shares of CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research note on Monday, May 13th. They issued an “overweight” rating and a $21.00 target price on the stock. Finally, Mizuho started coverage on shares of CytomX Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $16.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $20.72.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2019/06/15/fil-ltd-sells-454036-shares-of-cytomx-therapeutics-inc-nasdaqctmx.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: Hedge Funds

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.